tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Feb 7;10(2):250.
doi: 10.3390/vaccines10020250.
Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2
Arnau Boix-Besora[SUP] 1 [/SUP], Elianet Lorenzo[SUP] 1 [/SUP], Jesús Lavado-García[SUP] 1 [/SUP], Francesc Gòdia[SUP] 1 [/SUP], Laura Cervera[SUP] 1 [/SUP]
Affiliations
Abstract
Virus-like particles (VLPs) constitute a promising approach to recombinant vaccine development. They are robust, safe, versatile and highly immunogenic supra-molecular structures that closely mimic the native conformation of viruses without carrying their genetic material. HIV-1 Gag VLPs share similar characteristics with wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, making them a suitable platform for the expression of its spike membrane protein to generate a potential vaccine candidate for COVID-19. This work proposes a methodology for the generation of SARS-CoV-2 VLPs by their co-expression with HIV-1 Gag protein. We achieved VLP functionalization with coronavirus spike protein, optimized its expression using a design of experiments (DoE). We also performed the bioprocess at a bioreactor scale followed by a scalable downstream purification process consisting of two clarifications, an ion exchange and size-exclusion chromatography. The whole production process is conceived to enhance its transferability at current good manufacturing practice (cGMP) industrial scale manufacturing. Moreover, the approach proposed could be expanded to produce additional Gag-based VLPs against different diseases or COVID-19 variants.
Keywords: COVID-19; HEK293; HIV-1; SARS-CoV-2; VLP vaccines; bioprocess; design of experiments; downstream process; transient transfection.
. 2022 Feb 7;10(2):250.
doi: 10.3390/vaccines10020250.
Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2
Arnau Boix-Besora[SUP] 1 [/SUP], Elianet Lorenzo[SUP] 1 [/SUP], Jesús Lavado-García[SUP] 1 [/SUP], Francesc Gòdia[SUP] 1 [/SUP], Laura Cervera[SUP] 1 [/SUP]
Affiliations
- PMID: 35214708
- DOI: 10.3390/vaccines10020250
Abstract
Virus-like particles (VLPs) constitute a promising approach to recombinant vaccine development. They are robust, safe, versatile and highly immunogenic supra-molecular structures that closely mimic the native conformation of viruses without carrying their genetic material. HIV-1 Gag VLPs share similar characteristics with wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, making them a suitable platform for the expression of its spike membrane protein to generate a potential vaccine candidate for COVID-19. This work proposes a methodology for the generation of SARS-CoV-2 VLPs by their co-expression with HIV-1 Gag protein. We achieved VLP functionalization with coronavirus spike protein, optimized its expression using a design of experiments (DoE). We also performed the bioprocess at a bioreactor scale followed by a scalable downstream purification process consisting of two clarifications, an ion exchange and size-exclusion chromatography. The whole production process is conceived to enhance its transferability at current good manufacturing practice (cGMP) industrial scale manufacturing. Moreover, the approach proposed could be expanded to produce additional Gag-based VLPs against different diseases or COVID-19 variants.
Keywords: COVID-19; HEK293; HIV-1; SARS-CoV-2; VLP vaccines; bioprocess; design of experiments; downstream process; transient transfection.